Publication Name	World Journal of Gastroenterology
Manuscript ID	5837
Country	Japan

Received	2013-09-28 15:04
Peer-Review Started	2013-09-29 13:19
To Make the First Decision	2013-12-26 10:54
Return for Revision	2014-01-17 09:41
Revised	2014-01-20 20:04
Second Decision	2014-04-29 12:20
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-29 14:21
Articles in Press	2014-05-23 10:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-16 13:34
Publish the Manuscript Online	2014-08-07 10:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Topic Highlights
Article Title	Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs
Manuscript Source	Invited Manuscript
All Author List	Abbi R Saniabadi, Tomotaka Tanaka, Toshihide Ohmori, Koji Sawada, Takayuki Yamamoto and Hiroyuki Hanai
Funding Agency and Grant Number
Corresponding Author	Abbi R Saniabadi, PhD, Department of Pharmacology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan. saniabadi@jimro.co.jp
Key Words	Inflammatory bowel disease; Myeloid lineage leucocytes; Adsorptive granulocytes/monocytes apheresis; Corticosteroid sparing effect; Complement activation fragments; Treating inflammatory bowel disease without drugs
Core Tip	The efficacy of anti-tumour necrosis factor-α biologics has validated the role of inflammatory cytokines in the exacerbation of inflammatory bowel disease (IBD). However, inflammatory cytokines are released by patients’ own cellular elements including myeloid lineage leucocytes, which in patients with IBD are elevated with activation behaviour. Accordingly, these leucocytes appear logical targets of therapy and can be depleted by adsorptive granulocyte/monocyte apheresis (GMA). Therefore, in patients with IBD, there is a scope for removing from the body the sources of pro-inflammatory cytokines, and this should fulfill the desire to treat without drugs. Therefore, by introducing GMA at an early stage following the onset of IBD or before patients develop extensive mucosal damage, many patients should respond to GMA and avoid pharmacologics.
Publish Date	2014-08-07 10:34
Citation	Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715
URL	http://www.wjgnet.com/1007-9327/full/v20/i29/9699.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i29.9699

Full Article (PDF)	WJG-20-9699.pdf
Full Article (Word)	WJG-20-9699.doc
Manuscript File	5837-Review.doc
Answering Reviewers	5837-Answering reviewers.pdf
Copyright License Agreement	5837-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5837-Language certificate.pdf
Peer-review Report	5837-Peer reviews.pdf
Scientific Editor Work List	5837-Scientific editor work list.pdf